

Resource Summary Report

Generated by [dkNET](#) on Aug 26, 2026

PE/Cyanine7 anti-mouse CD103

RRID:AB_2563690

Type: Antibody

Proper Citation

BioLegend Cat# 121425, RRID:AB_2563690

Antibody Information

URL: http://antibodyregistry.org/AB_2563690

Proper Citation: BioLegend Cat# 121425, RRID:AB_2563690

Target Antigen: CD103

Host Organism: armenian hamster

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PE/Cyanine7 anti-mouse CD103

Description: This monoclonal targets CD103

Target Organism: mouse

Clone ID: Clone 2E7

Antibody ID: AB_2563690

Vendor: BioLegend

Catalog Number: 121425

Alternative Catalog Numbers: 121426

Record Creation Time: 20250820T014407+0000

Record Last Update: 20250820T114304+0000

Ratings and Alerts

No rating or validation information has been found for PE/Cyanine7 anti-mouse CD103.

No alerts have been found for PE/Cyanine7 anti-mouse CD103.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Dalangood S, et al. (2025) Cancer-associated adipocytes mediate CD8+T cell dysfunction via FGF21-driven lipolysis. Cell reports, 44(11), 116526.

Ciccone MF, et al. (2025) Loss of BPTF restores estrogen response and suppresses metastasis of mammary tumors. Nature communications, 16(1), 9168.

Tursi NJ, et al. (2025) Modulation of lipid nanoparticle-formulated plasmid DNA drives innate immune activation promoting adaptive immunity. Cell reports. Medicine, 6(4), 102035.

Vasquez JH, et al. (2025) Somatic Miwi2 modulates mitochondrial function in airway multiciliated cells and exacerbates influenza pathogenesis. iScience, 28(4), 112291.

Frey HC, et al. (2025) A membrane lipid signature unravels the dynamic landscape of group 1 innate lymphoid cells across the health-disease continuum. iScience, 28(3), 112043.

Benamar M, et al. (2025) Notch3 destabilizes regulatory T cells to drive autoimmune neuroinflammation in multiple sclerosis. Immunity, 58(11), 2753.

Green WD, et al. (2025) Enhancer-driven gene regulatory networks reveal transcription factors governing T cell adaptation and differentiation in the tumor microenvironment. Immunity, 58(7), 1725.

Huang CX, et al. (2024) Pericancerous cross-presentation to cytotoxic T lymphocytes impairs immunotherapeutic efficacy in hepatocellular carcinoma. Cancer cell, 42(12), 2082.

Hu C, et al. (2024) Tumor-secreted FGF21 acts as an immune suppressor by rewiring cholesterol metabolism of CD8+T cells. Cell metabolism, 36(3), 630.

Hänggi K, et al. (2024) Interleukin-1 β release during necrotic-like cell death generates myeloid-driven immunosuppression that restricts anti-tumor immunity. Cancer cell, 42(12), 2015.

Dan J, et al. (2023) Oncolytic virus M1 functions as a bifunctional checkpoint inhibitor to enhance the antitumor activity of DC vaccine. *Cell reports. Medicine*, 4(10), 101229.

Bhaskar A, et al. (2023) SIRT2 inhibition by AGK2 enhances mycobacteria-specific stem cell memory responses by modulating beta-catenin and glycolysis. *iScience*, 26(5), 106644.

Guendel F, et al. (2020) Group 3 Innate Lymphoid Cells Program a Distinct Subset of IL-22BP-Producing Dendritic Cells Demarcating Solitary Intestinal Lymphoid Tissues. *Immunity*, 53(5), 1015.

Zhang H, et al. (2020) CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer. *Cancer cell*, 37(1), 37.